<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04759781</url>
  </required_header>
  <id_info>
    <org_study_id>MERLIN_001</org_study_id>
    <nct_id>NCT04759781</nct_id>
  </id_info>
  <brief_title>MElanoma Research Lymph Node Prediction Implementation National_001</brief_title>
  <acronym>MERLIN_001</acronym>
  <official_title>A Prospective Registry Study of a Primary Melanoma Gene-signature to Predict Sentinel Node (SN) Status and Determine Its Prognostic Value for More Accurate Staging of SN-negative Melanoma Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SkylineDx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SkylineDx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MERLIN_001 is a prospective registry study of a primary melanoma gene-signature to predict&#xD;
      sentinel node (SN) status and to determine its prognostic value for more accurate staging of&#xD;
      SN-negative melanoma patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2021</start_date>
  <completion_date type="Anticipated">April 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Negative Predictive Value (NPV)</measure>
    <time_frame>2 years after inclusion</time_frame>
    <description>The predictive capability of the Merlin Assay to identify newly diagnosed primary cutaneous melanoma patients who have a low risk of presenting with a positive sentinel lymph node.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive Predictive Value (PPV)</measure>
    <time_frame>2 years after inclusion</time_frame>
    <description>The predictive capability of the Merlin Assay to identify newly diagnosed primary cutaneous melanoma patients who have a low risk of presenting with a positive sentinel lymph node.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity and Specificity.</measure>
    <time_frame>2 years after inclusion</time_frame>
    <description>The predictive capability of the Merlin Assay to identify newly diagnosed primary cutaneous melanoma patients who have a low risk of presenting with a positive sentinel lymph node.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-5 year Recurrence-Free Survival (RFS)</measure>
    <time_frame>3-5 years after patient inclusion</time_frame>
    <description>Time between the date of sentinel lymph node biopsy procedure and the date of first melanoma recurrence (loco-regional or distant metastasis) or date of death (whatever the cause), whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-5 year Distant Metastasis-Free Survival (DMFS)</measure>
    <time_frame>3-5 years after patient inclusion</time_frame>
    <description>Time between the date of sentinel lymph node biopsy procedure and the date of first distant metastasis or date of death (whatever the cause), whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-5 year Overall Survival (OS)</measure>
    <time_frame>3-5 years after patient inclusion</time_frame>
    <description>Time between the date of sentinel lymph node biopsy procedure and the date of death (whatever the cause).</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2130</enrollment>
  <condition>Melanoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Prospectively collected primary cutaneous melanoma patients who are elected per treating&#xD;
        physician's recommendation to undergo sentinel lymph node biopsy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed patients with invasive malignant melanoma of the skin (AJCC 8th&#xD;
             edition staging guidelines) elected to undergo sentinel lymph node biopsy per the&#xD;
             treating physician's recommendation.&#xD;
&#xD;
          -  Male or female, age â‰¥18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Full primary melanoma pathology report unavailable.&#xD;
&#xD;
          -  Documented clinically apparent nodal metastases at diagnosis.&#xD;
&#xD;
          -  Distant metastatic disease (M1a,b,c,d) clinically present at primary diagnosis&#xD;
&#xD;
          -  Any prior or concurrent primary invasive melanoma mapping to the same draining lymph&#xD;
             node basin(s).&#xD;
&#xD;
          -  Documented history of another (prior or concurrent) primary invasive melanoma of T1b&#xD;
             or greater at any site within the last 5 years.&#xD;
&#xD;
          -  Previous surgery in or radiation therapy to the draining lymph node basin(s) of the&#xD;
             current primary melanoma.&#xD;
&#xD;
          -  Ocular, vulvar, perianal or mucosal melanomas or melanocytic tumors of uncertain&#xD;
             malignant potential (MELTUMP) or atypical Spitz tumors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vernon K. Sondak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tina J. Hieken, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael E. Egger, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dennie Tempel, PhD</last_name>
    <phone>+31107200326</phone>
    <email>D.Tempel@skylinedx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashley van der Spek, MSc</last_name>
    <phone>+31107200326</phone>
    <email>a.vanderspek@skylinedx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vernon K. Sondak, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael C. Lowe, MD/MA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40292</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael E. Egger, MD/MPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina V. Angeles, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina J. Hieken, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prospective study</keyword>
  <keyword>gene expression</keyword>
  <keyword>melanoma</keyword>
  <keyword>Merlin</keyword>
  <keyword>assay</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

